Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

Arix Bioscience plc. (5/31/17). "Press Release: Arix Bioscience to Present at Jefferies 2017 Global Healthcare Conference in New York". London.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Arix Bioscience plc (LSE: ARIX)
  Today Arix Bioscience (Group)
  Group Arix Bioscience (Group)
  Organisation 2 Jefferies LLC
  Group Leucadia (Group)
Products Product Jefferies 2017 Global Healthcare Conference New York
  Product 2 venture capital
Index terms Index term Arix Bioscience–Leucadia: investor conference, 201706 supply service Arix Bioscience presents at Jefferies Healthcare Conference in New York
  Index term 2 Arix Bioscience–Consilium: public relations, 201705 service existent by Consilium Strategic Communications
Persons Person Anderson, Joe (Arix Bioscience 201809– Chief Investment Officer before CEO before Abingworth)
  Person 2 Karlsson, Jan-Anders (Verona Pharma 201403 CEO)

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US.

The presentation will be on Thursday, 8 June at 4pm EDT and a webcast of the presentation will be available for 90 days on the conference website.

Additionally, a number of Arix’s Group Businesses will be present at the conference, including:

Jan-Anders Karlsson, Chief Executive Officer of Verona Pharma plc, will present on Thursday, 8 June at 11.30am EDT. Verona Pharma is a listed clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet needs.

The management team at Autolus Ltd will attend the conference and will be available for 1-1 meetings. Autolus is a private biopharmaceutical company focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology.

For more information, please contact:

Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit

Record changed: 2017-08-24


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Arix Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top